Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neonatal Screening | 18 | 2022 | 96 | 2.910 |
Why?
|
| Cystic Fibrosis | 5 | 2005 | 110 | 0.760 |
Why?
|
| Severe Combined Immunodeficiency | 4 | 2021 | 53 | 0.680 |
Why?
|
| Infant, Newborn | 18 | 2022 | 1283 | 0.620 |
Why?
|
| Heptanoates | 1 | 2013 | 3 | 0.420 |
Why?
|
| Tyrosinemias | 1 | 2013 | 19 | 0.410 |
Why?
|
| Genetic Counseling | 2 | 2005 | 15 | 0.310 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2010 | 37 | 0.310 |
Why?
|
| Program Development | 2 | 2010 | 203 | 0.310 |
Why?
|
| Acyl-CoA Dehydrogenase | 1 | 2008 | 10 | 0.300 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2013 | 141 | 0.280 |
Why?
|
| Parents | 3 | 2005 | 367 | 0.270 |
Why?
|
| Genetic Testing | 2 | 2004 | 126 | 0.260 |
Why?
|
| Trypsinogen | 1 | 2004 | 6 | 0.230 |
Why?
|
| Needs Assessment | 1 | 2005 | 187 | 0.230 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2004 | 74 | 0.220 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 188 | 0.220 |
Why?
|
| Child Health Services | 1 | 2004 | 61 | 0.210 |
Why?
|
| Massachusetts | 5 | 2021 | 2019 | 0.200 |
Why?
|
| Metabolism, Inborn Errors | 3 | 2011 | 20 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2021 | 281 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2005 | 454 | 0.180 |
Why?
|
| Communication | 1 | 2005 | 545 | 0.180 |
Why?
|
| Program Evaluation | 3 | 2010 | 470 | 0.180 |
Why?
|
| Health Policy | 1 | 2002 | 177 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 328 | 0.150 |
Why?
|
| Pilot Projects | 4 | 2011 | 914 | 0.140 |
Why?
|
| Algorithms | 3 | 2010 | 974 | 0.140 |
Why?
|
| Sensitivity and Specificity | 3 | 2005 | 1091 | 0.130 |
Why?
|
| Infant | 4 | 2021 | 1491 | 0.130 |
Why?
|
| Humans | 18 | 2022 | 59366 | 0.130 |
Why?
|
| False Positive Reactions | 3 | 2012 | 76 | 0.120 |
Why?
|
| Aftercare | 2 | 2005 | 69 | 0.120 |
Why?
|
| Models, Organizational | 2 | 2005 | 92 | 0.120 |
Why?
|
| Decision Making, Organizational | 2 | 2005 | 25 | 0.110 |
Why?
|
| Genes, T-Cell Receptor | 2 | 2010 | 7 | 0.110 |
Why?
|
| Blood Specimen Collection | 2 | 2010 | 19 | 0.110 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 126 | 0.100 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 1 | 2010 | 9 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 1027 | 0.090 |
Why?
|
| Hematologic Tests | 1 | 2010 | 15 | 0.090 |
Why?
|
| Health Plan Implementation | 1 | 2010 | 40 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2005 | 725 | 0.090 |
Why?
|
| DNA | 2 | 2010 | 805 | 0.080 |
Why?
|
| Software | 1 | 2012 | 366 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 250 | 0.080 |
Why?
|
| Carnitine | 1 | 2008 | 18 | 0.080 |
Why?
|
| Infant Formula | 1 | 2008 | 11 | 0.070 |
Why?
|
| New England | 2 | 2010 | 267 | 0.070 |
Why?
|
| Point Mutation | 1 | 2008 | 160 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 332 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2010 | 525 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 394 | 0.070 |
Why?
|
| Attitude to Health | 2 | 2005 | 279 | 0.060 |
Why?
|
| Breast Feeding | 1 | 2008 | 143 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 705 | 0.060 |
Why?
|
| Parental Consent | 1 | 2005 | 6 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 1559 | 0.060 |
Why?
|
| Physician Executives | 1 | 2005 | 28 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2005 | 94 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2022 | 6069 | 0.060 |
Why?
|
| Genetic Carrier Screening | 1 | 2004 | 14 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2003 | 295 | 0.060 |
Why?
|
| Forecasting | 1 | 2004 | 220 | 0.050 |
Why?
|
| Child Development | 1 | 2003 | 80 | 0.050 |
Why?
|
| Biomarkers | 1 | 2008 | 1306 | 0.050 |
Why?
|
| Social Support | 1 | 2005 | 355 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 48 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 109 | 0.050 |
Why?
|
| Decision Making | 1 | 2005 | 395 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 551 | 0.050 |
Why?
|
| Informed Consent | 1 | 2002 | 138 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 297 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2004 | 405 | 0.040 |
Why?
|
| Incidence | 1 | 2004 | 1238 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2005 | 647 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2003 | 442 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2021 | 175 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2004 | 2375 | 0.040 |
Why?
|
| Time Factors | 1 | 2005 | 3615 | 0.040 |
Why?
|
| Male | 4 | 2011 | 27742 | 0.040 |
Why?
|
| Female | 4 | 2011 | 30719 | 0.030 |
Why?
|
| Mutation | 1 | 2004 | 2456 | 0.030 |
Why?
|
| Minnesota | 1 | 2012 | 38 | 0.020 |
Why?
|
| Metabolome | 1 | 2012 | 27 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 51 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 84 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 191 | 0.020 |
Why?
|
| Public Health Practice | 1 | 2010 | 15 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 40 | 0.020 |
Why?
|
| India | 1 | 2011 | 150 | 0.020 |
Why?
|
| Ribonucleases | 1 | 2010 | 31 | 0.020 |
Why?
|
| Calibration | 1 | 2010 | 67 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 60 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 71 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2010 | 54 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 333 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 902 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 486 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 931 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 495 | 0.020 |
Why?
|
| United States | 1 | 2002 | 7426 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 814 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 442 | 0.020 |
Why?
|
| Child | 2 | 2010 | 4187 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2010 | 423 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 2338 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2003 | 108 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 2003 | 159 | 0.010 |
Why?
|
| Health Status | 1 | 2003 | 425 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 1792 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2003 | 3067 | 0.010 |
Why?
|
| Hospitalization | 1 | 2003 | 1290 | 0.010 |
Why?
|
| Adult | 1 | 2003 | 15679 | 0.000 |
Why?
|